%0 Journal Article
%T Interaction of 5′-Guanosine Monophosphate with Organotin(IV) Moieties: Synthesis, Structural Characterization, and Anti-Inflammatory Activity
%A Mala Nath
%A Hitendra Singh
%A George Eng
%A Xueqing Song
%J ISRN Organic Chemistry
%D 2012
%R 10.5402/2012/873035
%X Reaction(s) of -guanosine monophosphate ( GMP) with di- and triorganotin(IV) chloride(s) led to formation of organotin(IV) derivatives of general formulae, [R2Sn( -GMP)·H2O]n and [(R′3Sn)2( -GMP)·H2O]n, where R？=？Me, n-Bu, and Ph; R′？=？Me, i-Pr, n-Bu, and Ph; ( -GMP)2？ = -guanosine monophosphate. An attempt has been made to prove the structures of the resulting derivatives on the basis of FT-IR, multinuclear 1H, 13C, and 119Sn NMR and 119Sn M？ssbauer spectroscopic studies. These investigations suggest that both di- and triorganotin(IV)- -guanosine monophosphates are polymeric in which ( -GMP)2？ is bonded through phosphate group resulting in a distorted trigonal bipyramidal geometry around tin. The ribose conformation in all of the derivatives is C3′-endo, except diphenyltin(IV) and tri-i-propyltin(IV) derivatives where it is C2′-endo. All of the studied derivatives exhibited mild-to-moderate anti-inflammatory activity (~15.64–20.63% inhibition) at 40？mg？kg？1 dose and LD50 values >？400？mg？kg？1 in albino rats. 1. Introduction The field of cancer chemotherapy has been developed enormously during the past fifty years. Prior to 1969, however, the arsenal of chemotherapeutic agents was devoid of compounds which are inorganic in nature because of generally accepted belief that most metals and their compounds were potentially carcinogenic [1]. In 1969, Rosenberg and his coworkers made the serendipitous discovery [2] that certain Pt compounds were potent antitumor agents against Sarcoma 180 tumors and L1210 leukemia in mice and must be considered to be an outstanding development in the field of metal compounds in medicine [3]. Cis-platin is the first drug from inorganic chemistry to have come under routine clinical use in medical oncology [3]; in 1986, it was the largest selling anticancer drug worldwide. Its success placed the co-ordination chemists on the front line in the fight against cancer and stimulated the search for other metal-containing compounds with potential anticancer activity. In last 20 years about more than 12000 complexes of 55 metals have been tested [4], many of them are now entering for clinical trials, and some may ultimately rival cis-platin [5–7]. Although the majority of these successes involved complexes containing transition metal ions such as Cr, Co, Cu, Pd, Rh, Ru, and Au [5–8], but some main group metals (i.e., Al, Ga, In, ad Tl; Ge, Sn, and Pb; Bi and Po) compounds [1], especially organotins, have also been discovered which show promise as future members of man’s anticancer arsenal [9–13]. Further, several organotin(IV)
%U http://www.hindawi.com/journals/isrn.organic.chemistry/2012/873035/